Cargando…
P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428909/ http://dx.doi.org/10.1097/01.HS9.0000969444.32459.0c |
| _version_ | 1785090583607377920 |
|---|---|
| author | Xu, Wei Feng, Ru Wang, LI Zhu, Huayuan Zhou, Keshu Fu, Xiaorui Jing, Hongmei Song, Yuqin Qi, Junyuan Cui, Guohui LI, Fei Wang, Shaoyuan Zhou, Hui Qian, Wenbin Cai, Qingqing Zhao, Xielan Guo, Xutao Wei, Xiaolei Lin, Ningjing Xu, Zhongyuan Wang, Zheng Xiao, Xiang Dong, Jiale Lou, Yejiang Shen, Yue Chen, Yi Chen, Yu Tan, Fenlai Anthony, Stephen LI, Jianyong |
| author_facet | Xu, Wei Feng, Ru Wang, LI Zhu, Huayuan Zhou, Keshu Fu, Xiaorui Jing, Hongmei Song, Yuqin Qi, Junyuan Cui, Guohui LI, Fei Wang, Shaoyuan Zhou, Hui Qian, Wenbin Cai, Qingqing Zhao, Xielan Guo, Xutao Wei, Xiaolei Lin, Ningjing Xu, Zhongyuan Wang, Zheng Xiao, Xiang Dong, Jiale Lou, Yejiang Shen, Yue Chen, Yi Chen, Yu Tan, Fenlai Anthony, Stephen LI, Jianyong |
| author_sort | Xu, Wei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428909 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104289092023-08-17 P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS Xu, Wei Feng, Ru Wang, LI Zhu, Huayuan Zhou, Keshu Fu, Xiaorui Jing, Hongmei Song, Yuqin Qi, Junyuan Cui, Guohui LI, Fei Wang, Shaoyuan Zhou, Hui Qian, Wenbin Cai, Qingqing Zhao, Xielan Guo, Xutao Wei, Xiaolei Lin, Ningjing Xu, Zhongyuan Wang, Zheng Xiao, Xiang Dong, Jiale Lou, Yejiang Shen, Yue Chen, Yi Chen, Yu Tan, Fenlai Anthony, Stephen LI, Jianyong Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428909/ http://dx.doi.org/10.1097/01.HS9.0000969444.32459.0c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Xu, Wei Feng, Ru Wang, LI Zhu, Huayuan Zhou, Keshu Fu, Xiaorui Jing, Hongmei Song, Yuqin Qi, Junyuan Cui, Guohui LI, Fei Wang, Shaoyuan Zhou, Hui Qian, Wenbin Cai, Qingqing Zhao, Xielan Guo, Xutao Wei, Xiaolei Lin, Ningjing Xu, Zhongyuan Wang, Zheng Xiao, Xiang Dong, Jiale Lou, Yejiang Shen, Yue Chen, Yi Chen, Yu Tan, Fenlai Anthony, Stephen LI, Jianyong P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS |
| title | P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS |
| title_full | P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS |
| title_fullStr | P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS |
| title_full_unstemmed | P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS |
| title_short | P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS |
| title_sort | p635: an update of safety and efficacy results from phase 1 study of lp-108, a novel and selective bcl-2 inhibitor, in patients with relapsed or refractory b-cell non-hodgkin lymphomas |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428909/ http://dx.doi.org/10.1097/01.HS9.0000969444.32459.0c |
| work_keys_str_mv | AT xuwei p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT fengru p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT wangli p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT zhuhuayuan p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT zhoukeshu p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT fuxiaorui p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT jinghongmei p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT songyuqin p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT qijunyuan p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT cuiguohui p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT lifei p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT wangshaoyuan p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT zhouhui p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT qianwenbin p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT caiqingqing p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT zhaoxielan p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT guoxutao p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT weixiaolei p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT linningjing p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT xuzhongyuan p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT wangzheng p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT xiaoxiang p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT dongjiale p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT louyejiang p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT shenyue p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT chenyi p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT chenyu p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT tanfenlai p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT anthonystephen p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas AT lijianyong p635anupdateofsafetyandefficacyresultsfromphase1studyoflp108anovelandselectivebcl2inhibitorinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomas |